RETACRIT

Vifor (International) Inc.🇺🇸 United States

FDA Page

Effective Date: May 12, 2023
Approval ID: e6e4dd0c-25ca-40b2-ba6b-6138a68621fe
Products: 6 registered
Version: 12

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilar to EPOGEN/PROCRIT (epoetin alfa)

Quick Stats

Total Products6

Labelers2

Label Sections37

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.